Mylotarg Phase IV Study In AML To Examine Combo Therapy For First-line Use
Executive Summary
Wyeth-Ayerst is planning a Phase IV study to evaluate Mylotarg in combination therapy for the treatment of patients recently diagnosed with CD33 positive acute myeloid leukemia, the company said.